

# 2025 Year in Review - Our Strongest Year to Date

10 Years of Transparent Reporting

## SHOWSTOPPERS<sup>1</sup>

**2,339% ROI**

Every \$1 invested generated \$23 in savings.



Lower Per Member Per Year (PMPY) spend for Reformulary clients than private market plans.



Savings for Reformulary clients.



Present value of savings from implementation-to-date.



Average ROI from implementation-to-date.

## SPECIALTY SPEND



Reformulary specialty drug growth rate is **half that of** private plans.

Active management matters.

## CLINICAL GOVERNANCE



Comprehensive drug reviews conducted with our Expert Committee.

Clinical rigour. Financial discipline.

## BIOSIMILAR LEADERSHIP<sup>3</sup>



Biosimilar penetration.

More than double the penetration across the full portfolio.

## INFLATION CONTROL<sup>2</sup>



Disciplined Growth.

● RG ● Private

## SERVICES SCALING



myRequest Navigation moved from launch to active member support.



meTrics enabled more Canadians to track how they feel.

## FOOTNOTES

<sup>1</sup> Reformulary growth compared to growth in all private market plans in our master analytics database, comprising data procured from private plans covering 426.6 million claims for 10.3 million claimants, representing \$19.1 billion in spend.

<sup>2</sup> Inflation calculated based on total paid amount for DINs on the Reformulary, including specialty drugs. For private plans, inflation calculated based on total paid amount for same DINs, for all private plans in our master analytics database.

<sup>3</sup> Biosimilar penetration for 'first four' calculated for active clients, based on biosimilar transition for first originator biologics: etanercept, adalimumab, infliximab, rituximab. Biosimilar penetration for 'all biologics' calculated for active clients, based on biosimilar transition of first four and all biologics including rituximab, ranibizumab, teriparatide, pegfilgrastim, ustekinumab, aflibercept, omalizumab, tocilizumab. Private market biosimilar penetration rates for both first four and all biologics calculated based on all private plans in our master analytics database.